Longboard Pharmaceuticals

longboard pharmaceuticals, inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific g protein-coupled receptors (gpcrs). longboard’s small molecule product candidates are based on more than 20 years of gpcr research. longboard is evaluating lp352, an oral, centrally acting 5-hydroxytryptamine 2c (5-ht2c) receptor superagonist, with negligible observed impact on 5-ht2b and 5-ht2a receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. longboard is also evaluating lp659, a centrally acting, sphingosine-1-phosphate (s1p) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and lp143, a centrally acting, full cannabinoid type 2 recept